Literature DB >> 24125151

Allergy training and immunotherapy in Latin America: results of a regional overview.

Carlos E Baena-Cagnani1, Désirée Larenas Linnemann, Maximiliano Gómez, Sandra González Díaz, Dirceu Solé, Mario Sánchez Borges, Jean Bousquet, Juan Carlos Sisul, Giorgio Walter Canonica, José Gereda, Giovanni Passalacqua.   

Abstract

BACKGROUND: One main practice gap in allergology that has been detected in several regions of the world is the application of specific immunotherapy (SIT). The prescription and practice of SIT should characterize allergologic specialists, but there are regional discrepancies in such practice. A detailed knowledge of the regulatory and legislation aspects and drawbacks would help improve and harmonize SIT practice.
OBJECTIVE: To describe in Latin America the level of allergy training and the characteristics of the use of SIT, including the medical and legal aspects.
METHODS: Three sources were used: a 24-item questionnaire sent to 22 allergologic leaders in 11 Latin American countries, 2 face-to-face meetings, and information from health authorities involved in the approval of medical substances.
RESULTS: In 56% of countries, the specialty of allergology is a third-level care specialty and/or a subspecialty. Two countries have a special training program for pediatric allergists. Passing a board examination is mandatory in 3 countries, and recertification every 2 to 5 years occurs without examination. Sublingual and subcutaneous SITs are available in all Latin American countries. No legislation restricts SIT prescription and it can be performed by nonspecialists in 7 of 11 countries. In 90% of countries, allergists use allergen extracts from the United States (subcutaneous immunotherapy) and Europe (sublingual and subcutaneous immunotherapies), and 50% also manufacture extracts locally. Only 1 country has legal requirements for the quality of raw materials.
CONCLUSION: The present analysis helps to identify gaps in the field of allergologic training and SIT in Latin America, many of them amendable.
Copyright © 2013 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 24125151     DOI: 10.1016/j.anai.2013.08.011

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  4 in total

Review 1.  Current status and future perspectives of immunotherapy in Latin America and Cuba.

Authors:  Alexander Diaz Rodriguez; Alexis Labrada Rosado; Raúl Lázaro Castro Almarales; Mirta Álvarez Castelló
Journal:  World Allergy Organ J       Date:  2014-11-12       Impact factor: 4.084

Review 2.  Challenges of managing food allergy in the developing world.

Authors:  Elham Hossny; Motohiro Ebisawa; Yehia El-Gamal; Stefania Arasi; Lamia Dahdah; Rasha El-Owaidy; Cesar A Galvan; Bee Wah Lee; Michael Levin; Santiago Martinez; Ruby Pawankar; Mimi L K Tang; Elizabeth H Tham; Alessandro Fiocchi
Journal:  World Allergy Organ J       Date:  2019-12-02       Impact factor: 4.084

Review 3.  Current situation of allergy education in Mexico and other parts of Latin America.

Authors:  Sandra Nora Gonzalez-Diaz; Bryan Martin; Cindy Elizabeth de Lira-Quezada; Rosalaura Virginia Villarreal-Gonzalez; Rosa Ivett Guzman-Avilan; Alejandra Macías-Weinmann; José Antonio Ortega-Martell; Carlos Macouzet-Sanchez; Mario Sánchez-Borges; Nelson Augusto Rosario Filho; Anahí Yañez; María Antonieta Guzman-Melendez; Ricardo Cardona; Olga Patricia Monge-Ortega; Ivan Cherrez-Ojeda; Dayanara Herrera-Castro; Marylin Valentin-Rostan; Juan Carlos Sisul-Alvariza; Ignacio J Ansotegui; Barbara Elizondo-Villarreal
Journal:  World Allergy Organ J       Date:  2021-05-18       Impact factor: 4.084

4.  Allergen immunotherapy on the way to product-based evaluation-a WAO statement.

Authors:  Claus Bachert; Mark Larché; Sergio Bonini; Giorgio Walter Canonica; Thomas Kündig; Desiree Larenas-Linnemann; Dennis Ledford; Hugo Neffen; Ruby Pawankar; Giovanni Passalacqua
Journal:  World Allergy Organ J       Date:  2015-09-16       Impact factor: 4.084

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.